Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis. (3rd May 2020)
- Record Type:
- Journal Article
- Title:
- Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis. (3rd May 2020)
- Main Title:
- Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis
- Authors:
- Wijnen, Ben F.M.
Thielen, Frederick W.
Konings, Steef
Feenstra, Talitha
Van Der Gaag, Mark
Veling, Wim
De Haan, Lieuwe
Ising, Helga
Hiligsmann, Mickaël
Evers, Silvia M.A.A.
Smit, Filip
Lokkerbol, Joran - Abstract:
- ABSTRACT: Background: This study aims to report on the design of a model to determine the cost-effectiveness of prevention and treatment of early psychosis (PsyMod) and to estimate ten-year cost-effectiveness and budget impact of interventions targeting individuals with ultra-high risk (UHR) of developing psychosis or with first episode psychosis (FEP). Methods: PsyMod was built in parallel with the development of a new standard of care for treatment of early psychosis in the Netherlands. PsyMod is a state-transition cohort simulation model and considers six health states, namely ultra-high risk of psychosis (UHR), FEP, post-FEP, no-UHR, recovery/remission, and death. Results are expressed as total healthcare costs, QALYs, incremental cost-effectiveness ratio (ICER), and budget impact. Results: PsyMod was used to extrapolate budget impact and cost-effectiveness of cognitive behavioural therapy for preventing FEP for individuals at UHR of psychosis (CBTuhr) compared to care as usual. CBTuhr resulted in a per-patient increase of 0.06 QALYs and a per patient cost reduction of €654 (dominant ICER) with a reduction in 5-year healthcare costs of €1, 002, 166. Conclusions: PsyMod can be used to examine cost-effectiveness and budget impact of interventions targeting prevention and treatment of FEP and is freely available for academic purposes upon request by the authors.
- Is Part Of:
- Expert review of pharmacoeconomics & outcomes research. Volume 20:Number 3(2020)
- Journal:
- Expert review of pharmacoeconomics & outcomes research
- Issue:
- Volume 20:Number 3(2020)
- Issue Display:
- Volume 20, Issue 3 (2020)
- Year:
- 2020
- Volume:
- 20
- Issue:
- 3
- Issue Sort Value:
- 2020-0020-0003-0000
- Page Start:
- 269
- Page End:
- 279
- Publication Date:
- 2020-05-03
- Subjects:
- Schizophrenia -- psychosis -- health economic modelling -- economic evaluation -- budget impact -- cost-effectiveness
Pharmacology -- Economic aspects -- Periodicals
338.47615105 - Journal URLs:
- http://www.future-drugs.com/loi/erp ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/14737167.2019.1632194 ↗
- Languages:
- English
- ISSNs:
- 1473-7167
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3842.002996
British Library DSC - BLDSS-3PM
British Library HMNTS - Digital store
British Library HMNTS - ELD Digital store - Ingest File:
- 22949.xml